JPMorgan Chase Earned More in 2025 Than Bank of America and Wells Fargo Combined. Can the Stock Keep Outrunning Them?

JPMorgan shares are up nearly 130% since early October 2023, versus less than 100% for Bank of America and Wells Fargo, and the article argues JPMorgan’s larger corporate and investment banking business may support further relative outperformance. Investment banking fees and principal transactions made up over 40% of JPMorgan’s non-interest revenue in 2025, compared with 12% from investment banking at Bank of America; the article also says more than half of JPMorgan’s bottom line came from investment banking and corporate-oriented services. Higher rates and sluggish activity are weighing on loan demand: mortgage applications were down roughly 24% year over year, while potential IPOs could boost capital-markets activity; worsening economic conditions remain a risk for all three banks.

Analysis

The relative-value case is not simply “higher rates help JPM more”: it depends on capital-markets activity converting into realized fees, while a weak economy can simultaneously suppress loan growth, trading appetite and deal execution. A prospective IPO pipeline is optionality, not booked revenue; issuers can defer, resize or choose other banks, and a handful of mega-deals would not by itself establish a durable earnings run-rate. JPM’s larger markets exposure can therefore amplify both upside and earnings volatility versus BAC, not just provide insulation from soft consumer borrowing.

The key near-term check is actual investment-banking fee growth and management commentary on mandates converting to launches—not IPO speculation. Over 1–3 months, deal announcements and quarterly bank results can change the relative narrative; over 6–18 months, consumer credit, deposit costs and loan demand may regain importance. A renewed growth scare or prolonged issuance freeze would undercut the thesis, while a consumer-credit rebound without a capital-markets recovery could favor BAC/WFC comparatively. The article’s historical share-performance comparison is not a valuation argument; without relative valuation, estimate revisions and current positioning, chasing JPM after prior outperformance has unattractive evidentiary support.

Key Decisions for Investors

• Prefer a conditional relative-value setup over an outright bank-sector bet: consider long JPM versus short BAC only after evidence of improving fee conversion (reported investment-banking fees, announced offerings and guidance). Size modestly; the pair loses if consumer-led bank earnings recover while issuance remains stalled, or if JPM’s valuation premium expands without estimate upgrades.
• Keep WFC as a watch rather than assume it is a clean substitute for BAC: compare current loan/deposit trends, credit costs and capital-markets contribution before adding it to the short leg. The article does not provide enough data to rank their downside precisely.
• For the next 1–3 months, monitor IPO filings/pricing and quarterly fee revenue, alongside loan growth, deposit costs and credit provisions. Treat a rumored pipeline as insufficient confirmation; a material decline in deal launches or weaker fee guidance falsifies the near-term JPM-relative thesis.
• Avoid paying up for the narrative after JPM’s prior relative strength. Reassess if reported capital-markets fees fail to improve, or if consumer lending and credit metrics strengthen enough to shift earnings revisions toward BAC/WFC; no absolute price target is supported by the supplied information.